@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk> .
@prefix sub: <http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix mondo: <http://purl.obolibrary.org/obo/MONDO_> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  drugbank:DB01104 a biolink:Drug;
    rdfs:label "sertraline";
    biolink:category biolink:Drug .
  
  mondo:0008114 a biolink:Disease;
    rdfs:label "obsessive-compulsive disorder";
    biolink:category biolink:Disease .
  
  sub:association a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    rdf:object mondo:0008114;
    rdf:predicate biolink:treats;
    rdf:subject drugbank:DB01104;
    rdfs:label "Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78].";
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    biolink:has_population_context sub:context;
    biolink:publications pmid:30101713;
    biolink:relation ncit:C94303 .
  
  sub:context a biolink:Cohort;
    rdfs:label "adults";
    biolink:category biolink:Cohort .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
    npx:hasSignature "M7gktdbiNUgTK9MQ2fCjlG/ldf2/3FUNLKyY44iK8dgCUk1BtoZyE/3UjniS47B1kyn26A1ZK3GuJpZNespnWE32XB5m9b9lWhYhus1sDOtoc7hKqZH7Dz045S95TwJCr1s9hbEVs3ZM7rhVpsiv8utyodP/Yl+E3enS9DLotGM=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2022-09-16T11:53:49.145453"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-1501-1082;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
  
  biolink: pav:version "2.3.0" .
}